US Patent

US11324696 — Suspensions and diluents for metronidazole and baclofen

Formulation · Assigned to Azurity Pharmaceuticals Inc · Expires 2037-09-29 · 11y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations for suspensions of metronidazole or baclofen, including various additives such as stabilizers and preservatives.

USPTO Abstract

Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.

Drugs covered by this patent

Patent Metadata

Patent number
US11324696
Jurisdiction
US
Classification
Formulation
Expires
2037-09-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Azurity Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.